Scientists Identify Two Brain Cell Types Behaving Differently in Depression Patients, Paving Way for Targeted Therapies

Scientists led by Drs. Gustavo Turecki, Corina Nagy, and Yue Li identified two brain cell types behaving differently in depression patients in a study published Tuesday in *Nature Genetics*. Using single-cell genomic analysis of post-mortem brain tissue from the Douglas-Bell Canada Brain Bank, the researchers found altered gene activity in excitatory neurons and microglia, which they said could explain molecular disruptions linked to depressive symptoms.

The study, published Tuesday in *Nature Genetics*, marks the first time researchers have identified specific brain cell types with altered activity linked to depression, according to Dr. Gustavo Turecki, a professor at McGill University and clinician-scientist at the Douglas Institute.

Using single-cell genomic techniques, the team analyzed post-mortem brain tissue from 59 individuals diagnosed with depression and 41 without, sourced from the Douglas-Bell Canada Brain Bank, one of the few global repositories with psychiatric condition samples.

The researchers focused on the prefrontal cortex, a brain region implicated in mood regulation and stress response. They found significant disruptions in gene expression and DNA regulation within two cell types: excitatory neurons and a subtype of microglia. Excitatory neurons, which play a critical role in mood and stress regulation, exhibited altered gene functioning consistent with previous findings of neuronal pathology in major depressive disorder, Dr. Turecki said. Many genes involved in neurotransmitter systems, including glutamate pathways, operated differently in depression patients, suggesting molecular breakdowns that may underlie depressive symptoms.

The microglia subtype, known for managing brain inflammation and immune responses, also showed distinct gene expression changes associated with inflammation regulation. These alterations were unique to the depression samples and indicate a biological role for immune system dysfunction in depressive pathology, according to the study’s findings. Dr. Turecki noted that the microglial changes support a biological basis for depression beyond psychological factors.

The single-cell genomic approach allowed the team to analyze RNA and DNA from thousands of individual brain cells. This method enabled the mapping of gene activity alongside DNA regulatory mechanisms, providing a detailed picture of molecular disruptions at the cellular level. Dr. Yue Li, a collaborator on the project, contributed to the analysis that revealed how DNA regulation sequences differ between depressed and non-depressed individuals, further explaining the functional differences observed in the affected cells.

Dr. Corina Nagy, co-lead on the study, emphasized that the combined gene expression and DNA code mapping was critical in pinpointing the specific cell types involved in depression. The research was conducted through the Turecki and Nagy laboratories at McGill University and the Douglas Institute in Montreal, Canada.

The findings have implications for developing targeted therapies for depression, which affects an estimated 264 million people worldwide, according to the World Health Organization. By identifying the precise cell types and molecular pathways disrupted in depression, the study lays the groundwork for next-generation antidepressants that could specifically target excitatory neurons and microglia to address mood regulation and brain inflammation. Dr. Turecki highlighted that this cellular-level understanding challenges previous misconceptions about depression and opens new avenues for precise interventions.

The Douglas-Bell Canada Brain Bank, which provided the tissue samples, is recognized internationally for its extensive collection of brains from individuals with psychiatric disorders, enabling studies like this to advance understanding of mental illness biology. Future research may integrate this cell-specific data with resources such as the Allen Brain Atlas to further elucidate the molecular and cellular landscape of depression.

Dr. Turecki holds the Canada Research Chair in Major Depressive Disorder and Suicide and leads ongoing efforts to translate these molecular insights into clinical applications. The study’s publication in *Nature Genetics* on June 18, 2024, underscores the growing role of genomic technologies in psychiatric research and the potential to transform treatment approaches for complex brain disorders.